Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy

Published:2016-11 Issue: Volume:Volume 10 Page:2397-2406
ISSN:1177-889X
Container-title:Patient Preference and Adherence
language:en
Short-container-title:PPA

Author:

Kleinberg Lawrence^ORCID

Publisher

Informa UK Limited

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Social Sciences (miscellaneous),Medicine (miscellaneous)

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing cancer therapy: Unveiling the cutting-edge potential of carmustine nano carriers for targeted treatment;Journal of Drug Delivery Science and Technology;2024-09

2. Evaluating the Efficacy of Carmustine Combined with Temozolomide in the Treatment of Glioma Following Minimally Invasive Surgery;International Journal of Pharmacology;2023-11-01

3. Recent Advancements and Strategies for Overcoming the Blood–Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma;Polymers;2023-10-02

4. Drug delivery breakthrough technologies – A perspective on clinical and societal impact;Journal of Controlled Release;2023-08

5. How to Develop Drug Delivery System Based on Carbohydrate Nanoparticles Targeted to Brain Tumors;Polymers;2023-05-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP